In this exploratory study, we identified SNPs in regulatory regions of SLC22A4 and SLC22A5 genes, coding imatinib transporters, which were significantly associated with outcome of imatinib in CML patients. Here, SLC22A5 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.